Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 12/20 | 0.69 |
| ▸ | PPARG | P37231 | 3/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | CPA3 | P15088 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5053346 | 0.87 | FOLH1 (0.60) | FOLH1PPARGPPARAPTGESALOX5 | |
| SCHEMBL5060105 | 0.85 | FOLH1 (0.64) | FOLH1PPARGPTGESALOX5CPA3 | |
| SCHEMBL28893490 | 0.84 | CYP1A2 (0.65) | FOLH1PPARGPPARAMMEACE | |
| SCHEMBL5054359 | 0.83 | FOLH1 (1.00) | FOLH1CPA1CPA3 | |
| SCHEMBL5058027 | 0.82 | FOLH1 (0.75) | FOLH1CPA3 | |
| SCHEMBL22764737 | 0.81 | FOLH1 (0.52) | FOLH1PPARGPPARAPTGESALOX5 | |
| SCHEMBL5054395 | 0.80 | FOLH1 (0.70) | FOLH1ACECPA3 | |
| SCHEMBL2058464 | 0.80 | FOLH1 (1.00) | FOLH1 | |
| SCHEMBL5060115 | 0.77 | FOLH1 (0.67) | FOLH1CPA3 | |
| SCHEMBL5053199 | 0.76 | FOLH1 (0.66) | FOLH1PPARGPPARACPA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992215-B2 | Thiol-based NAALADase inhibitors | GUILDFORD PHARMACEUTICALS INC. (US) | 2006-01-31 | — | — | US | claimed |
| US-20050085503-A1 | Thiol-based NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC, | 2005-04-21 | — | — | US | claimed |
| WO-2002057222-A9 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARM INC (US) | 2004-05-06 | — | — | WO | claimed |
| US-20030216468-A1 | Thiol-based NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. | 2003-11-20 | — | — | US | claimed |
| EP-1353903-A2 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2003-10-22 | — | — | EP | claimed |
| US-20030105088-A1 | Thiol-based NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. | 2003-06-05 | — | — | US | claimed |
| WO-2002057222-A2 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-07-25 | — | — | WO | claimed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| WO-2006093991-A1 | COMPOUNDS WHICH BIND PSMA AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216468-A1 | Thiol-based NAALADase inhibitors | NAALAD2, GLUL, RIMKLA | FOLH1 6/4885PPARG 3596/4885PPARA 3929/4885 |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | FOLH1 1/4885PPARG 751/4885PPARA 361/4885 |
| US-20030105088-A1 | Thiol-based NAALADase inhibitors | NAALAD2, GLUL, RIMKLA | FOLH1 6/4885PPARG 3596/4885PPARA 3929/4885 |
| US-20050085503-A1 | Thiol-based NAALADase inhibitors | NAALAD2, GLUL, FOLH1 | FOLH1 3/4885PPARG 3478/4885PPARA 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.